Peroxitech

Peroxitech Therapeutics is a biopharmaceutical company dedicated to treating acute lung injury (ALI) by developing novel peptides to target newly identified disease manifestation pathways. Their lead compound, PIP-2, can eliminate reactive oxygen species (ROS) that accumulate in the lungs, which can cause respiratory failure, hypoxemia, and tissue acidosis associated with acute lung injury, regardless of its etiology.